Genprex, Inc. (GNPX)
NASDAQ: GNPX · IEX Real-Time Price · USD
1.40
+0.04 (2.94%)
At close: Jun 24, 2022 4:00 PM
1.41
+0.01 (0.86%)
After-hours:
Jun 24, 2022 5:15 PM EDT
Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 17 |
| CEO | J. Rodney Varner |
Contact Details
Address:
1601 Trinity St Bldg B Austin, Texas 78712-1765 United States | |
| Phone | 877 774 4679 |
| Website | genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001595248 |
Key Executives
| Name | Position |
|---|---|
| John Rodney Varner | Co-Founder, Chairman, President and Chief Executive Officer |
| Ryan M. Confer M.S. | Chief Financial Officer |
| Catherine M. Vaczy Esq. | Executive Vice President, General Counsel, Corporate Secretary and Chief Strategy Officer |
| Dr. Hemant Kumar C.P.M., EMBA, Ph.D. | Chief Manufacturing and Technology Officer |
| Kalyn Dabbs | Senior Manager of Communications and Marketing |
| David M. Schloss | Senior Vice President of Human Resources |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
| Dr. William E. Gannon Jr. | Member of Clinical Advisory Board and Vice President of Regulatory Affairs |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| Greg Jancarik C.M.A., CPA, M.B.A. | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 5, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 5, 2022 | 8-K | Current report |
| Apr 28, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2022 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2022 | 8-K | Current report |
| Apr 14, 2022 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2022 | 8-K | Current report |
| Mar 30, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Mar 2, 2022 | 8-K | Current report |